Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CURTIS J DUNSHEE

Allopathic & Osteopathic Physicians Urology

NPI
1538161880
CMS profile
296524
Location
TUCSON, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,249.16

71 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,249.16 71

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CURTIS J DUNSHEE

NPI 1538161880 · CMS profile ID 296524

Allopathic & Osteopathic Physicians / Urology

TUCSON, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538161880?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CURTIS J DUNSHEE, NPI 1538161880, CMS profile ID 296524. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538161880?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CURTIS J DUNSHEE, NPI 1538161880, CMS profile ID 296524. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538161880?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CURTIS J DUNSHEE, NPI 1538161880, CMS profile ID 296524, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1538161880?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

71 matching records · $1,249.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 71 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–71 of 71.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Myovant Sciences Inc. $17.3604/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941196033 CMS
Bayer HealthCare Pharmaceuticals Inc. $11.4204/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930589597 CMS
Dendreon Pharmaceuticals LLC $29.2504/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943098879 CMS
Dendreon Pharmaceuticals LLC $19.4304/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943098881 CMS
PFIZER INC. $9.4704/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949111273 CMS
Merck Sharp & Dohme LLC $20.7204/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944149877 CMS
Myovant Sciences Inc. $27.4204/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941196031 CMS
Coloplast Corp $18.8404/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941086543 CMS
Janssen Biotech, Inc. $21.2104/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885519385 CMS
Myovant Sciences Inc. $24.3904/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941196025 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.5203/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930606779 CMS
TOLMAR Pharmaceuticals, Inc. $23.4503/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954446559 CMS
Myovant Sciences Inc. $10.2503/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941196023 CMS
Bayer HealthCare Pharmaceuticals Inc. $12.7703/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930597371 CMS
TOLMAR Pharmaceuticals, Inc. $17.1203/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954471261 CMS
Myovant Sciences Inc. $17.5302/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941196017 CMS
UROVANT SCIENCES INC $18.5501/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 931047017 CMS
Dendreon Pharmaceuticals LLC $15.5701/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943098877 CMS
Myovant Sciences Inc. $2.6001/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941196015 CMS
Coloplast Corp $14.4601/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941086503 CMS
Myovant Sciences Inc. $18.5601/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941196009 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23,640.62 94
PY2020 $7,807.51 56
PY2021 $4,677.56 52
PY2022 $1,249.16 71
PY2023 $5,902.79 65
PY2024 $2,426.19 83
PY2025 $718.49 28

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $21,510.00 15
PY2025 Principal investigator $1,386,082.00 101
PY2024 Recipient $18,950.00 12
PY2024 Principal investigator $2,378,147.02 164
PY2023 Recipient $25,230.00 21
PY2023 Principal investigator $1,949,173.64 144
PY2022 Recipient $3,200.00 1
PY2022 Principal investigator $2,429,227.31 214
PY2021 Recipient $5,066.33 4
PY2021 Principal investigator $2,777,315.99 159
PY2020 Recipient $4,330.00 5
PY2020 Principal investigator $3,054,970.61 180
PY2019 Recipient $7,386.09 20
PY2019 Principal investigator $1,959,773.49 164

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

116 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $640.90 12/16/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228747464
Principal investigator 1 Dendreon Pharmaceuticals LLC $300.00 12/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS
PROVONE STUDY No dispute reported 06/30/2026 1247892665
Principal investigator 1 PFIZER INC. $2,500.00 11/26/2025 Non-covered Recipient Entity
Arizona Urology Specialists PLLC AUS Research
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 No dispute reported 06/30/2026 1228729268
Principal investigator 1 PFIZER INC. $46,207.89 11/19/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726308
Principal investigator 1 PFIZER INC. $46,207.89 11/18/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726306
Principal investigator 1 PFIZER INC. $46,207.89 11/10/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727835
Principal investigator 1 PFIZER INC. $46,207.89 11/08/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228719871
Principal investigator 1 Dendreon Pharmaceuticals LLC $750.00 11/06/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS
PROVONE STUDY No dispute reported 06/30/2026 1247892581
Principal investigator 1 Sumitomo Pharma America, Inc. $40.00 11/05/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654634
Principal investigator 1 Sumitomo Pharma America, Inc. $40.00 11/05/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654682
Principal investigator 1 Sumitomo Pharma America, Inc. $800.00 11/05/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654815
Principal investigator 1 Sumitomo Pharma America, Inc. $2,161.00 11/05/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654824
Principal investigator 1 Sumitomo Pharma America, Inc. $40.00 11/05/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654853
Recipient PFIZER INC. $330.00 11/03/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727343
Principal investigator 1 PFIZER INC. $18,918.00 10/25/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228742263
Principal investigator 1 Janssen Research & Development, LLC $252.00 09/05/2025 Non-covered Recipient Entity
Urological Associates Of Sthrn Arizona PC Admin Ofc
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175166867
Principal investigator 1 Astellas Pharma Global Development $400.00 09/04/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234181806
Principal investigator 1 PFIZER INC. $92,415.77 08/21/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726324
Principal investigator 1 PFIZER INC. $92,415.77 08/20/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726394
Principal investigator 1 Janssen Research & Development, LLC $475.00 08/18/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175345364
Principal investigator 1 PFIZER INC. $101.00 08/09/2025 Non-covered Recipient Entity
Arizona Urology Specialists PLLC AUS Research
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228786531
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,000.00 08/08/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS
PROVONE STUDY No dispute reported 06/30/2026 1247892381
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,000.00 08/08/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS
PROVONE STUDY No dispute reported 06/30/2026 1247892384
Principal investigator 1 Janssen Research & Development, LLC $3,250.00 08/04/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175345401
Principal investigator 1 PFIZER INC. $1,193.00 07/25/2025 Non-covered Recipient Entity
Arizona Urology Specialists PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228773528
Principal investigator 1 PFIZER INC. $5,574.35 07/11/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228782082
Principal investigator 1 Sumitomo Pharma America, Inc. $40.00 07/09/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176640476
Principal investigator 1 PFIZER INC. $101.00 07/01/2025 Non-covered Recipient Entity
Arizona Urology Specialists PLLC AUS Research
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 No dispute reported 06/30/2026 1228764749
Principal investigator 1 PFIZER INC. $2,047.50 06/26/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228720425
Principal investigator 1 Janssen Research & Development, LLC $7,284.00 06/23/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175345335
Principal investigator 1 Janssen Research & Development, LLC $7,284.00 06/23/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175345389
Principal investigator 1 Sumitomo Pharma America, Inc. $14,541.00 06/18/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176636377
Principal investigator 1 Sumitomo Pharma America, Inc. $580.50 06/18/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176636382
Principal investigator 1 Sumitomo Pharma America, Inc. $11,601.60 06/18/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176636386
Recipient PFIZER INC. $940.00 06/14/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228724344
Principal investigator 1 Janssen Research & Development, LLC $5,138.00 06/09/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175345341
Recipient Dendreon Pharmaceuticals LLC $9,750.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891311
Principal investigator 1 Dendreon Pharmaceuticals LLC $9,750.00 06/05/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS
ProvONE No dispute reported 06/30/2026 1247891970
Principal investigator 1 Dendreon Pharmaceuticals LLC $9,626.00 06/05/2025 Non-covered Recipient Entity
CENTERS FOR ADVANCED UROLOGY
ProvONE No dispute reported 06/30/2026 1247892160
Principal investigator 1 Janssen Research & Development, LLC $7,984.00 06/02/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175345425
Principal investigator 1 MEDIVATION LLC. $1,628.90 06/02/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228780538
Principal investigator 1 MEDIVATION LLC. $1,628.90 06/02/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790200
Principal investigator 1 MEDIVATION LLC. $325.00 06/02/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791983
Principal investigator 1 MEDIVATION LLC. $325.00 06/02/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792101
Principal investigator 1 MEDIVATION LLC. $325.00 06/02/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792593
Principal investigator 1 PFIZER INC. $46,206.12 06/02/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752859
Recipient PFIZER INC. $940.00 06/02/2025 Covered Recipient Physician PF06821497 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228771253
Principal investigator 1 PFIZER INC. $46,206.12 06/01/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752325
Recipient PFIZER INC. $940.00 05/31/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228752898
Recipient PFIZER INC. $940.00 05/31/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228768730
Principal investigator 1 Janssen Research & Development, LLC $350.00 05/29/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175345306
Principal investigator 1 PFIZER INC. $46,206.12 05/27/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753837
Principal investigator 1 Janssen Research & Development, LLC $15,277.00 05/23/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175345372
Principal investigator 1 PFIZER INC. $1,592.50 05/23/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228772318
Principal investigator 1 PFIZER INC. $46,206.12 05/22/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228753139
Principal investigator 1 Janssen Research & Development, LLC $3,269.00 05/19/2025 Non-covered Recipient Entity
Arizona Uro Specialists Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175164781
Principal investigator 1 Janssen Research & Development, LLC $252.00 05/16/2025 Non-covered Recipient Entity
Urological Associates Of Sthrn Arizona PC Admin Of
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175166876
Principal investigator 1 PFIZER INC. $11,147.50 05/14/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228772478
Principal investigator 1 PFIZER INC. $250.00 05/08/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALIST
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228763239
Principal investigator 1 MEDIVATION LLC. $325.00 05/05/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228790439
Principal investigator 1 MEDIVATION LLC. $1,628.90 05/05/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791666
Principal investigator 1 MEDIVATION LLC. $698.75 05/05/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792167
Recipient PFIZER INC. $330.00 05/01/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228771496
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,630.41 04/30/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1185539551
Principal investigator 1 Janssen Research & Development, LLC $2,569.00 04/28/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175345275
Principal investigator 1 Janssen Research & Development, LLC $2,688.00 04/24/2025 Non-covered Recipient Entity
Arizona Uro Specialists Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175164797
Principal investigator 1 PFIZER INC. $2,434.70 04/24/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228797243
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,200.00 04/23/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) No dispute reported 06/30/2026 1185539557
Recipient PFIZER INC. $330.00 04/18/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228767513
Principal investigator 1 Sumitomo Pharma America, Inc. $6,192.25 04/09/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632523
Principal investigator 1 Sumitomo Pharma America, Inc. $11,965.50 04/09/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632780
Principal investigator 1 Sumitomo Pharma America, Inc. $3,000.00 04/09/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176632835
Principal investigator 1 Sumitomo Pharma America, Inc. $875.00 04/09/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176632838
Principal investigator 1 PFIZER INC. $64,203.40 04/08/2025 Non-covered Recipient Entity
Arizona Urology Specialists PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1228779520
Principal investigator 1 PFIZER INC. $47,619.28 04/08/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228780316
Principal investigator 1 Janssen Research & Development, LLC $7,284.00 04/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175345348
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,875.32 04/02/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185539553
Principal investigator 1 MEDIVATION LLC. $1,628.90 04/01/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792918
Recipient PFIZER INC. $3,200.00 03/27/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770806
Principal investigator 1 MEDIVATION LLC. $8,060.00 03/21/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775737
Principal investigator 1 Astellas Pharma Global Development $1,000.00 03/19/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234181804
Principal investigator 1 Janssen Research & Development, LLC $2,688.00 03/17/2025 Non-covered Recipient Entity
Arizona Uro Specialists Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175164789
Principal investigator 1 PFIZER INC. $46,206.12 03/14/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752329
Principal investigator 1 PFIZER INC. $46,206.12 03/13/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754222
Principal investigator 1 Janssen Research & Development, LLC $5,138.00 03/07/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175345297
Principal investigator 1 PFIZER INC. $46,206.12 03/04/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754218
Principal investigator 1 MEDIVATION LLC. $325.00 03/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774356
Principal investigator 1 MEDIVATION LLC. $698.75 03/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774373
Principal investigator 1 MEDIVATION LLC. $325.00 03/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774645
Principal investigator 1 MEDIVATION LLC. $325.00 03/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774843
Principal investigator 1 MEDIVATION LLC. $325.00 03/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776359
Principal investigator 1 MEDIVATION LLC. $325.00 03/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776541
Principal investigator 1 MEDIVATION LLC. $698.75 03/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777735
Principal investigator 1 MEDIVATION LLC. $325.00 03/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778577
Principal investigator 1 MEDIVATION LLC. $325.00 03/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228786553
Principal investigator 1 PFIZER INC. $46,206.12 03/03/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751917
Principal investigator 1 Janssen Research & Development, LLC $27,846.00 02/21/2025 Non-covered Recipient Entity
Arizona Uro Specialists Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175164774
Principal investigator 1 PFIZER INC. $9,169.59 02/14/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228760974
Recipient PFIZER INC. $940.00 02/13/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228759663
Recipient PFIZER INC. $940.00 02/13/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770593
Principal investigator 1 Janssen Research & Development, LLC $5,188.00 02/10/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175345407
Principal investigator 1 Janssen Research & Development, LLC $350.00 02/07/2025 Non-covered Recipient Entity
Arizona Uro Specialists Pllc
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175164764
Principal investigator 1 Janssen Research & Development, LLC $112.00 02/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175345319
Principal investigator 1 Janssen Research & Development, LLC $475.00 02/03/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175345381
Recipient PFIZER INC. $940.00 02/03/2025 Covered Recipient Physician PF06821497 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228759635
Principal investigator 1 AstraZeneca Pharmaceuticals LP $41,276.44 01/29/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185539555
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician PF06821497 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228723488
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760331
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760650
Principal investigator 1 PFIZER INC. $1,755.00 01/25/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228798510
Principal investigator 1 PFIZER INC. $15,036.00 01/24/2025 Non-covered Recipient Entity
Arizona Urology Specialists PLLC AUS Research
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228801655
Principal investigator 1 Janssen Research & Development, LLC $252.00 01/10/2025 Non-covered Recipient Entity
Urological Associates Of Sthrn Arizona PC Admin Of
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1175167183
Principal investigator 1 PFIZER INC. $184,831.55 01/10/2025 Non-covered Recipient Entity
Urological Associates of Southern Arizona PC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228762259
Principal investigator 1 MEDIVATION LLC. $1,628.90 01/02/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775926
Principal investigator 1 MEDIVATION LLC. $8,060.00 01/02/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228785609
Principal investigator 1 MEDIVATION LLC. $1,628.90 01/02/2025 Non-covered Recipient Entity
ARIZONA UROLOGY SPECIALISTS PLLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228785612